|
Side Effects & Drug Interactions
ADVERSE REACTIONS
The incidence of common adverse reactions is based upon two U. S. and five non-U. S. controlled clinical trials in 1, 526 patients [110 females and 239 males less than 18 years of age, and 635 females and 542 males 18 years of age and older] treated with RHINOCORT AQUA Nasal Spray at doses up to 400 mcg once daily for 3Ð 6 weeks. The table below describes adverse events occurring at an incidence of 2% or greater and more common among RHINOCORT AQUA Nasal Spray-treated patients than in placebo-treated patients in controlled clinical trials. The overall incidence of adverse events was similar between RHINOCORT AQUA and placebo. 
Text Continues Below
A similar adverse event profile was observed in the subgroup of pediatric patients 6 to 12 years of age. Two to three percent (2Ð 3%) of patients in clinical trials discontinued because of adverse events. Systemic corticosteroid side effects were not reported during controlled clinical studies with RHINOCORT AQUA Nasal Spray. If recommended doses are exceeded, however, or if individuals are partic-ularly sensitive, symptoms of hypercorticism, ie, Cushing's Syndrome, could occur.
Rare adverse events reported from post-marketing experience include: nasal septum perforation, pharynx disorders (throat irritation, throat pain, swollen throat, burning throat, and itchy throat), angioedema, anosmia, and palpitations. Cases of growth suppression have been reported for intranasal cortico-steroids including RHINOCORT AQUA Nasal Spray (see PRECAUTIONS, Pediatric Use). Drug Interactions The main route of metabolism of budesonide, as well as other cortico-steroids, is via cytochrome P450 3A (CYP3A). After oral administration of ketoconazole, a potent inhibitor of cytochrome P450 3A, the mean plasma concentration of orally administered budesonide increased by more than seven-fold. Concomitant administration of other known inhibitors of CYP3A (eg, itraconazole, clarithromycin, erythromycin, etc.) may inhibit the metabolism of, and increase the systemic exposure to, budesonide (see WARNINGS and PRECAUTIONS, General). Omeprazole, an inhibitor of cytochrome P450 2C19, did not have effects on the pharmacokinetics of oral budesonide, while cimetidine, primarily an inhibitor of cytochrome P450 1A2, caused a slight decrease in budesonide clearance and corresponding increase in its oral bioavailability. Page: 1 | 2 | 3 | 4 | Next >>
|
.gif)
